A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3

Foster, GR; Chayama, K; Chuang, W-L; Fainboim, H; Farkkila, M; Gadano, A; Gaeta, GB; Hezode, C; Inada, Y; Heo, J; Kumada, H; Lu, S-N; Marcellin, P; Moreno, C; Roberts, SK; Strasser, SI; Thompson, AJ; Toyota, J; Paik, SW; Vierling, JM; Zignego, AL; Cohen, D; McPhee, F; Wind-Rotolo, M; Srinivasan, S; Hruska, M; Myler, H; Portsmouth, SD

Volume

DOI

10.1186/s40064-016-2920-z

Journal

SPRINGERPLUS

ISSN

2193-1801

Metadata

Show full item record

Authors

Foster, GR; Chayama, K; Chuang, W-L; Fainboim, H; Farkkila, M; Gadano, A; Gaeta, GB; Hezode, C; Inada, Y; Heo, J

URI

http://qmro.qmul.ac.uk/xmlui/handle/123456789/15696

Collections

Centre for Immunobiology [1160]

Licence information

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.